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INTRODUCTION
Glioblastoma with primitive neuronal components (GB/PNC) is a rare and emerging variant 
of GB, accounting for almost 0.5% cases of GB.[10] Primitive neuronal tumors are aggressive 
neoplasms of the central nervous system (CNS) that derives from cells of the primitive 
neuroectoderm. ese neoplasms generally appear in children; however, when they are associated 
with glial growth that they are more frequent in adults. Until few years ago, these tumors were 
called primitive neuroectodermal tumors (PNET), but after the last classification of tumors of the 
CNS by the World Health Organization (WHO), this term fell into disuse and began to be called 
tumors with PNC.[6] Histologically, GB/PNC have characteristics of both entities, and some of the 
genetic alterations present in each type of tumor may coexist in GB/PNC.[2] e low prevalence of 
these tumors and few cases published to date make it difficult to understand the pathophysiology 
of GB/PNC and although there are therapeutic strategies for glioblastomas and tumors with 
PNC, there is currently no standard treatment regimen for GB/PNC. Most of the times, these 
tumors are treated with surgery combining radiation therapy and chemotherapy according to 
specific therapeutic regimes for glioblastomas and tumors with PNC. Despite the optimization of 
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treatment, it has not been possible to elucidate aspects related 
to surgical treatment or the efficacy of adjuvant therapy, and 
the prognosis is unfavorable in most cases.
We present the case of a 77-year-old female patient with a 
GB/PNC that is treated with surgery and radiochemotherapy 
according to the STUPP protocol and where an abnormal 
uptake of 5-aminolevulinic acid (5-ALA) during surgery in 
probable relationship with the mixed nature of GB/PNC.
CASE REPORT
We present the case of a 77-year-old woman with a history 
of hypertension, dyslipidemia, and atrial fibrillation who 
presented with hemiparesis and left hemihypoesthesia 
of 4 months of evolution. Magnetic resonance imaging 
(MRI) showed an expansive intracranial lesion at the right 
frontoparietal level with abundant perilesional edema, areas 
that enhance paramagnetic contrast and a marked restriction 
of diffusion in the peripheral region [Figure  1]. Suspecting 
a high-grade primary brain tumor, a fluorescence-guided 
total resection with 5-ALA was performed, showing a tumor 
tissue of solid consistency, pale appearance, and with poor 
uptake of fluorescent marker [Figure  2]. e intraoperative 
histological study suggested a high-grade glial tumor. After 
surgery, the patient gradually recovered her motor balance, 
although the left hemihypoesthesia persisted. e definitive 
histological study revealed a GB/PNC with a high cellular 
proliferation index (Ki-67 95%) [Figures  3 and 4]. e 
isocitrate dehydrogenase (IDH)-1 R132H mutation was 
negative. IDH sequencing and the IDH-2 mutation were not 
determined. e study of the 1p19q codeletion was negative. 
e average methylation percentage of O6-methylguanine-
DNA methyltransferase (MGMT) was 66.2% [Figure  5]. 
e patient received the first line of adjuvant treatment 
with conventional radiotherapy and chemotherapy with 
temozolomide according to the STUPP protocol. Two weeks 
after completing radiotherapy treatment, the patient suffered 
a worsening of her neurological state and died.
DISCUSSION
GB/PNC is a rare variant of GB that exhibits very aggressive 
behavior. As with “conventional” GBs, they are considered 
Grade IV tumors according to the classification of CNS 
tumors of the WHO.[2] GB/PNC has characteristics of both 
types of tumor. As with “conventional” GBs, GB/PNC shows 
aggressive behavior with a high risk of local recurrence. On 
the other hand, they have a higher risk of leptomeningeal 
spread, as occurs with tumors with PNC. To date, the 
etiopathogenesis of GB/PNC is unknown, although the most 
consistent hypothesis is neuroblastic metaplasia, that is, the 
presence of foci of tumor primitive neuronal cells in pre-
existing, generally secondary glioblastomas.[9]
Figure  1: Magnetic resonance imaging with diffusion sequence 
shows an important restriction of diffusion in the peripheral region.
Figure  2: Intraoperative image showing a tumor lesion in the 
subcortical region with a weak fluorescence of the tumor tissue after 
administration of 5-aminolevulinic acid.
Figure 3: Hematoxylin-eosin stain showing both tumor components 
and transition area (×2).
Genetically, GB/PNC can present genetic alterations 
similar to “gliomas,” such as the 10q and 1p/19q deletions 
or the amplification of the gene encoding the epidermal 
growth factor receptor, and characteristics similar to those 
traditionally called “Primitive neuroectodermal tumors 
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Figure 5: Average percentage of MGMT methylation.
(PNET),” such as the high Ki-67 index or the amplification 
of the N-myc or C-myc genes. Cases of GB/PNC have been 
discovered with mutations in the enzyme IDH-1, which 
supports the origin of these tumors from secondary GB 
and seems to have a positive prognostic value.[11] Likewise, 
mutations of the gene encoding the MGMT promoter 
have been identified. Histologically, GB/PNC shows the 
characteristics of both malignancies. On the one hand, they 
present areas of high-grade glial growth with high expression 
of gliofibrillar acid protein (GFAP) and, on the other hand, 
areas of undifferentiated neuroepithelial hypercellularity with 
low expression of GFAP and neuronal immunophenotype 
(S-100, synaptophysin, neuronal nuclei, neuron-specific 
enolase, and neurofilament protein).[2]
Regarding imaging, although the MRI findings do not allow 
a distinction to be made between a “conventional” GB and a 
GB/PNC; the reduction of the apparent diffusion coefficient 
and the restriction in diffusion may be more evident probably 
due to the hypercellularity of the PNC.[1] In our case, it was 
not possible to determine the existence of a GB/PNC by 
MRI. e MRI showed a heterogeneous lesion with wide 
contrast uptake at the edges, a marked restriction of the 
peripheral diffusion and an area of central necrosis, being the 
radiological diagnosis of glioblastoma.
e treatment of these tumors is based on surgery, 
radiotherapy, and chemotherapy. Surgery plays a primary 
role in the treatment of high-grade gliomas and has been 
associated with increased survival in those patients treated 
with complete resection and adjuvant radiochemotherapy 
compared to conservatively treated patients.[5]
Guided fluorescence with 5-ALA facilitates surgical resection 
of high-grade gliomas since it allows to differentiate tumor 
tissue from healthy brain parenchyma during surgery. 
Once administered to the patient, 5-ALA is absorbed by 
the different tissues of the body and especially by malignant 
Figure 4: (a) Hematoxylin-eosin stain showing a tumor with dense cellularity and glomeruloid vessels GB-compatible (×10). (b) Hematoxylin-
eosin stain showing atypical cellularity with marked nuclear pleomorphism and abundant mitosis (×20). (c) Gliofibrillar acid protein (GFAP) 
staining showing glial line hypercellularity (×10). (d) Synaptophysin staining showing negative immunoreactivity (×10). (e) MIB-1 staining 
showing the proliferation index of glioblastoma (×10). (f) Anti-isocitrate dehydrogenase (IDH)-1 R132H immunohistochemistry showing 
absence of IDH-1 mutation (IDH wild-type GB) (×10). (g) Hematoxylin-eosin stain showing solid-looking primitive nodules presenting 
neuronal differentiation separated by a desmoplasic stroma (×10). (h) Hematoxylin-eosin stain showing high nuclear-cytoplasmic ratio, 
karyorrhexis, and occasional cell wrapping (×20). (i) GFAP staining showing low GFAP expression within the foci of the primitive neuronal 
component in contrast to the glioma component (×10). (j) Synaptophysin staining showing positive immunoreactivity in primitive cells 
(×10). (k) MIB-1 staining showing a high Ki-67 labeling index with nuclear positivity for more than 90% of tumor cells PNC-compatible 
(×10). (l) Anti-IDH-1 R132H immunohistochemistry showing a negative study for primitive neuronal component (×10).
a b c d e f
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glial cells. When applying a light with a wavelength of 
400–410 nm on the tumor tissue using a surgical microscope, 
protoporphyrin IX emits intense, strong pink fluorescence, 
allowing the extent of the malignant glioma to be determined 
and the resection to be guided.
5-ALA is a natural precursor to hemoglobin that is metabolized 
in the mitochondria, causing fluorescent protoporphyrins, such 
as protoporphyrin IX. e accumulation of protoporphyrin 
IX by tumor cells depends on the activity of certain 
mitochondrial enzymes, such as ferrokelase. High levels of 
ferrokelase have been shown to promote the accumulation of 
protoporphyrin IX in tumor cells of glioblastomas, bladder 
cancer, and lung cancer.[8] Likewise, low levels of certain 
membrane transporters, such as the ATP-binding transporter 
member 2 of the G superfamily (ABCG2), are also associated 
with an increase in the accumulation of protoporphyrin IX in 
glioblastoma tumor cells.[3]
In relation to CNS tumors, the concentration of 
protoporphyrin IX is considerably higher in malignant glial 
cells than in neurons, healthy glial cells, or neoplastic non-
glial cells. Marbacher et al.,[7] determined the percentage 
of patients who had positive uptake with 5-ALA in a 
retrospective review of 512 patients with brain tumors 
operated on by resection or stereotactic biopsy. e results 
of their study showed positive uptake in 88.4% of high-
grade gliomas, in 40% of low-grade gliomas, in 77.3% of 
meningiomas, and in 52.3% of brain metastases, among 
other tumors. So far, there is no evidence in the literature 
on the behavior of GB/PNC when treated with fluorescence-
guided surgery. In our case, despite being a malignant 
glioma, the intensity of the fluorescence was low. e mixed 
tumor nature and the presence of areas with primitive neural 
components with little uptake of 5-ALA could explain this 
phenomenon.
Due to the low prevalence, there is no standard treatment for 
GB/PNC. Most of the data are derived from small series or 
case reports. e largest series correspond to Varlet et al.[12] 
and Perry et al.[9] and in them aggressive therapy with radical 
surgery plus chemotherapy with temozolomide and adjuvant 
radiotherapy is recommended, being able to associate platinum-
derived drugs early to avoid recurrences derived from PNC. In 
other more recent studies, the possibility of associating cisplatin 
or carboplatin with standard treatment with temozolomide is 
suggested to reduce the risk of cerebrospinal fluid spread from 
PNC derived tumor cells.[4] As with “conventional” GBs, the 
response rate to treatment is higher in tumors with the presence 
of MGMT promoter methylation; however, in GB/PNC, 
there is no standard therapeutic protocol. Despite the correct 
treatment, the prognosis of these tumors remains unfavorable 
and, as with glioblastomas, it represents a therapeutic challenge 
for all professionals.
CONCLUSION
GB/PNC are extremely rare malignant tumors of the brain. 
e existence of a mixed tumor progression limits the image 
diagnosis and supposes a therapeutic dilemma. Fluorescence-
guided resection with 5-ALA is the surgical treatment 
of choice in surgery for high-grade gliomas; however, in 
GB/PNC, it may not be as useful since PNC may have less 
fluorescent marker uptake and be more dimly visualized 
when excited by light using the surgical microscope. To 
date, there is no standard treatment protocol for GB/PNC 
and in the reports or case series described in the literature, 
there is a tendency to recommend a combined therapy for 
both tumors. In spite of everything, the prognosis remains 
unfortunate and the contribution of new cases or studies 
with a greater casuistry can contribute to the understanding 
of the pathophysiology and establish a targeted therapeutic 
approach for these malignancies.
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